- Home
- VEL vs RLMD Comparison
VEL vs RLMD Comparison
Compare VEL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | RLMD |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 765.5M | 661.9M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VEL | RLMD |
|---|---|---|
| Price | $17.18 | $5.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.00 | $12.40 |
| AVG Volume (30 Days) | 89.7K | ★ 2.4M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.98 | ★ 45.28 |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $6.01 | N/A |
| Revenue Next Year | $19.02 | N/A |
| P/E Ratio | $30.23 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $16.19 | $0.55 |
| 52 Week High | $21.40 | $8.00 |
Technical Indicators
Market Signals| Indicator | VEL | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 35.49 |
| Support Level | $16.97 | $4.06 |
| Resistance Level | $17.98 | $7.28 |
| Average True Range (ATR) | 0.53 | 0.42 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 4.97 | 26.07 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. Company operates in a large fragmented market with substantial demand for financing and limited supply of institutional financing alternative The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.